Professor | Li Kun Gong | Asia Growth Partners

Name	Li Kun Gong
Contact Information	lkgong@simm.ac.cn
Language ability	Chinese, English, Japanese
Province	Shanghai

Name

Li Kun Gong

Contact Information

lkgong@simm.ac.cn

Language ability

Chinese, English, Japanese

Province

Shanghai

University/Lab Affiliation and Title	University of Chinese Academy of Sciences
Faculty	Medical School
Academic Background & Achievements	2002-09--2005-07 PhD: Graduate School of the Chinese Academy of Sciences 1997-09--2000-06 Master's Degree: China Medical University 1991-09--1996-07 Bachelor's Degree: China Medical University
Work Experience	2011-09~Present - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Researcher, Group Leader, Deputy Director of Safety Evaluation Center 2006-11~2008-12 - University of Tokyo, Japan - JSPS Foreign Special Researcher 2005-10~2011-09 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Associate Researcher 2000-07~2011-07 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Project Leader, Department Head, Assistant to the Head of the Center 1996-07~1997-09 - Shenyang Ligong University Hospital - Doctor
Awards	Science and Technology Progress Award (2017): First Prize, City Level Chinese Pharmaceutical Association Science and Technology Award (2016): First Prize, Ministry Level Research on Molecular Toxicology of Drugs and Key Technologies for New Drug Safety Evaluation and International Recognition (2013): Second Prize, National Level Chinese Pharmaceutical Association Science and Technology Award (2009): First Prize, Provincial Level Young Excellent Paper Award at the Fifth National Academic Conference of the Chinese Society of Toxicology (2009) JSPS Award (2006) Outstanding Young Scientific and Technological Worker Award (2004)

University/Lab Affiliation and Title

University of Chinese Academy of Sciences

Faculty

Medical School

Academic Background & Achievements

2002-09--2005-07 PhD: Graduate School of the Chinese Academy of Sciences
1997-09--2000-06 Master's Degree: China Medical University
1991-09--1996-07 Bachelor's Degree: China Medical University

Work Experience

2011-09~Present - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Researcher, Group Leader, Deputy Director of Safety Evaluation Center
2006-11~2008-12 - University of Tokyo, Japan - JSPS Foreign Special Researcher
2005-10~2011-09 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Associate Researcher
2000-07~2011-07 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Project Leader, Department Head, Assistant to the Head of the Center
1996-07~1997-09 - Shenyang Ligong University Hospital - Doctor

Awards

Science and Technology Progress Award (2017): First Prize, City Level
Chinese Pharmaceutical Association Science and Technology Award (2016): First Prize, Ministry Level
Research on Molecular Toxicology of Drugs and Key Technologies for New Drug Safety Evaluation and International Recognition (2013): Second Prize, National Level
Chinese Pharmaceutical Association Science and Technology Award (2009): First Prize, Provincial Level
Young Excellent Paper Award at the Fifth National Academic Conference of the Chinese Society of Toxicology (2009)
JSPS Award (2006)
Outstanding Young Scientific and Technological Worker Award (2004)

Areas of Focus	Pharmacology and Toxicology Traditional Chinese Medicine Pharmacology
Publications	Development and Validation of an ADA-Tolerant Assay for Quantification of an Exatecan-Based ADC in Monkey Plasma., Not mentioned, 2024 Excessive fatty acids activate PRMT5/MDM2/Drosha pathway to regulate miRNA biogenesis and lipid metabolism., Not mentioned, 2024 Construction of stable membranal CMTM6-PD-L1 full-length complex to evaluate the PD-1/PD-L1-CMTM6 interaction and develop anti-tumor anti-CMTM6 nanobody., Not mentioned, 2023 Towards a comprehensive view of the herpes B virus., Not mentioned, 2023 Identification of 3H-benzo[b] [1,4] diazepine derivatives as PPAR�� agonists by in silico studies and biochemical evaluation., Not mentioned, 2023 Development, methodological evaluation and application of a cell-based TRF assay for analysis of ADCC activity., Not mentioned, 2023 Preventive and therapeutic benefits of nelfinavir in rhesus macaques and human beings infected with SARS-CoV-2, Not mentioned, 2023 Development of a bridging ELISA for detection of antibodies against ZV0203 in cynomolgus monkey serum, Not mentioned, 2023 Development, Validation and Application of a Bridging ELISA for Detection of Antibodies against GQ1001 in Cynomolgus Monkey Serum, Not mentioned, 2023 Suppression of Tumor or Host Intrinsic CMTM6 Drives Antitumor Cytotoxicity in a PD-L1-Independent Manner, Not mentioned, 2023 D3AI-Spike: A deep learning platform for predicting binding affinity between SARS-CoV-2 spike receptor binding domain with multiple amino acid mutations and human angiotensin-converting enzyme 2, Not mentioned, 2022 Multi-Omics Integration Analysis Identifies Lipid Disorder of a Non-Alcoholic Fatty Liver Disease (NAFLD) Mouse Model Improved by Zexie-Baizhu Decoction, Not mentioned, 2022 CoVac501, a self-adjuvanting peptide vaccine conjugated with TLR7 agonists, against SARS-CoV-2 induces protective immunity, Not mentioned, 2022 PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way, Not mentioned, 2022 Predicting spike protein NTD mutations of SARS-CoV-2 causing immune evasion by molecular dynamics simulations, Not mentioned, 2022 Novel triterpenoids from Alisma plantago-aquatica with influence on LDL uptake in HepG2 cells by inhibiting PCSK9, Not mentioned, 2022 Different Immunoregulation Roles of Activin A Compared With TGF-��, Not mentioned, 2022 Transforming primary human hepatocytes into hepatocellular carcinoma with genetically defined factors, Not mentioned, 2022 Copy Number Analyses Identified a Novel Gene: APOBEC3A Related to Lipid Metabolism in the Pathogenesis of Preeclampsia, Not mentioned, 2022 Aberrant peribiliary gland niche exacerbates fibrosis in primary sclerosing cholangitis and a potential therapeutic strategy, Not mentioned, 2022 Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy, Not mentioned, 2022 Exploring the Binding Affinity and Mechanism between ACE2 and the Trimers of Delta and Omicron Spike Proteins by Molecular Dynamics Simulation and Bioassay, Not mentioned, 2022 One-step synthesis of site-specific antibody-drug conjugates by reprograming IgG glycoengineering with LacNAc-based substrates, Not mentioned, 2022 MicroRNA-379-5p regulates free cholesterol accumulation and relieves diet induced-liver damage in db/db mice via STAT1/HMGCS1 axis, Not mentioned, 2022 Current Analytical Strategies for Antibody-Drug Conjugates in Biomatrices, Not mentioned, 2022 Simultaneous solubilization and extended release of insoluble drug as payload in highly soluble particles of ��-cyclodextrin metal-organic frameworks, Not mentioned, 2022 Construction of stable membranal CMTM6-PD-L1 full-length complex to evaluate the PD-1/PD-L1-CMTM6 interaction and develop anti-tumor anti-CMTM6 nanobody, Not mentioned, 2022 Kupffer cells play a crucial role in monocrotaline-induced liver injury by producing TNF-alpha, Not mentioned, 2022 CSAD Ameliorates Lipid Accumulation in High-Fat Diet-Fed Mice, Not mentioned, 2022 New laboratory evidence for the association between endothelial dysfunction and COVID-19 disease progression, Not mentioned, 2022 SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2, Not mentioned, 2022 国内新药临床前研究阶段的安全药理学研究概况, Not mentioned, 2021 miR-552-3p modulates transcriptional activities of FXR and LXR to ameliorate hepatic glycolipid metabolism disorder, Not mentioned, 2021 MiR-337-3p lowers serum LDL-C level through targeting PCSK9 in hyperlipidemic mice, Not mentioned, 2021 Research progress on the protective effects of licorice-derived 18 beta-glycyrrhetinic acid against liver injury, Not mentioned, 2021 GADD45�� stabilized by direct interaction with HSP72 ameliorates insulin resistance and lipid accumulation, Not mentioned, 2021 Aristolochic acid I promoted clonal expansion but did not induce hepatocellular carcinoma in adult rats, Not mentioned, 2021 Prevention of D-GalN/LPS-induced ALI by 18 beta-glycyrrhetinic acid through PXR-mediated inhibition of autophagy degradation, Not mentioned, 2021 A new recombinant MS-superoxide dismutase alleviates 5-fluorouracil-induced intestinal mucositis in mice, Not mentioned, 2020 SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2, Not mentioned, 2020 新药非临床安全药理学研究进展, Not mentioned

Areas of Focus

Pharmacology and Toxicology
Traditional Chinese Medicine Pharmacology

Publications

Development and Validation of an ADA-Tolerant Assay for Quantification of an Exatecan-Based ADC in Monkey Plasma., Not mentioned, 2024
Excessive fatty acids activate PRMT5/MDM2/Drosha pathway to regulate miRNA biogenesis and lipid metabolism., Not mentioned, 2024
Construction of stable membranal CMTM6-PD-L1 full-length complex to evaluate the PD-1/PD-L1-CMTM6 interaction and develop anti-tumor anti-CMTM6 nanobody., Not mentioned, 2023
Towards a comprehensive view of the herpes B virus., Not mentioned, 2023
Identification of 3H-benzo[b] [1,4] diazepine derivatives as PPAR�� agonists by in silico studies and biochemical evaluation., Not mentioned, 2023
Development, methodological evaluation and application of a cell-based TRF assay for analysis of ADCC activity., Not mentioned, 2023
Preventive and therapeutic benefits of nelfinavir in rhesus macaques and human beings infected with SARS-CoV-2, Not mentioned, 2023
Development of a bridging ELISA for detection of antibodies against ZV0203 in cynomolgus monkey serum, Not mentioned, 2023
Development, Validation and Application of a Bridging ELISA for Detection of Antibodies against GQ1001 in Cynomolgus Monkey Serum, Not mentioned, 2023
Suppression of Tumor or Host Intrinsic CMTM6 Drives Antitumor Cytotoxicity in a PD-L1-Independent Manner, Not mentioned, 2023
D3AI-Spike: A deep learning platform for predicting binding affinity between SARS-CoV-2 spike receptor binding domain with multiple amino acid mutations and human angiotensin-converting enzyme 2, Not mentioned, 2022
Multi-Omics Integration Analysis Identifies Lipid Disorder of a Non-Alcoholic Fatty Liver Disease (NAFLD) Mouse Model Improved by Zexie-Baizhu Decoction, Not mentioned, 2022
CoVac501, a self-adjuvanting peptide vaccine conjugated with TLR7 agonists, against SARS-CoV-2 induces protective immunity, Not mentioned, 2022
PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way, Not mentioned, 2022
Predicting spike protein NTD mutations of SARS-CoV-2 causing immune evasion by molecular dynamics simulations, Not mentioned, 2022
Novel triterpenoids from Alisma plantago-aquatica with influence on LDL uptake in HepG2 cells by inhibiting PCSK9, Not mentioned, 2022
Different Immunoregulation Roles of Activin A Compared With TGF-��, Not mentioned, 2022
Transforming primary human hepatocytes into hepatocellular carcinoma with genetically defined factors, Not mentioned, 2022
Copy Number Analyses Identified a Novel Gene: APOBEC3A Related to Lipid Metabolism in the Pathogenesis of Preeclampsia, Not mentioned, 2022
Aberrant peribiliary gland niche exacerbates fibrosis in primary sclerosing cholangitis and a potential therapeutic strategy, Not mentioned, 2022
Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy, Not mentioned, 2022
Exploring the Binding Affinity and Mechanism between ACE2 and the Trimers of Delta and Omicron Spike Proteins by Molecular Dynamics Simulation and Bioassay, Not mentioned, 2022
One-step synthesis of site-specific antibody-drug conjugates by reprograming IgG glycoengineering with LacNAc-based substrates, Not mentioned, 2022
MicroRNA-379-5p regulates free cholesterol accumulation and relieves diet induced-liver damage in db/db mice via STAT1/HMGCS1 axis, Not mentioned, 2022
Current Analytical Strategies for Antibody-Drug Conjugates in Biomatrices, Not mentioned, 2022
Simultaneous solubilization and extended release of insoluble drug as payload in highly soluble particles of ��-cyclodextrin metal-organic frameworks, Not mentioned, 2022
Construction of stable membranal CMTM6-PD-L1 full-length complex to evaluate the PD-1/PD-L1-CMTM6 interaction and develop anti-tumor anti-CMTM6 nanobody, Not mentioned, 2022
Kupffer cells play a crucial role in monocrotaline-induced liver injury by producing TNF-alpha, Not mentioned, 2022
CSAD Ameliorates Lipid Accumulation in High-Fat Diet-Fed Mice, Not mentioned, 2022
New laboratory evidence for the association between endothelial dysfunction and COVID-19 disease progression, Not mentioned, 2022
SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2, Not mentioned, 2022
国内新药临床前研究阶段的安全药理学研究概况, Not mentioned, 2021
miR-552-3p modulates transcriptional activities of FXR and LXR to ameliorate hepatic glycolipid metabolism disorder, Not mentioned, 2021
MiR-337-3p lowers serum LDL-C level through targeting PCSK9 in hyperlipidemic mice, Not mentioned, 2021
Research progress on the protective effects of licorice-derived 18 beta-glycyrrhetinic acid against liver injury, Not mentioned, 2021
GADD45�� stabilized by direct interaction with HSP72 ameliorates insulin resistance and lipid accumulation, Not mentioned, 2021
Aristolochic acid I promoted clonal expansion but did not induce hepatocellular carcinoma in adult rats, Not mentioned, 2021
Prevention of D-GalN/LPS-induced ALI by 18 beta-glycyrrhetinic acid through PXR-mediated inhibition of autophagy degradation, Not mentioned, 2021
A new recombinant MS-superoxide dismutase alleviates 5-fluorouracil-induced intestinal mucositis in mice, Not mentioned, 2020
SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2, Not mentioned, 2020
新药非临床安全药理学研究进展, Not mentioned

Pharmacology Toxicology Drug Safety Traditional Chinese Medicine Herbal Medicine Molecular Toxicology Safety Evaluation Drug Development Pharmacodynamics Pharmacokinetics

Han Kun Hu - Wuhan University

Kou Hao - Wuhan University

Hui Wang - Wuhan University

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us